1 Underwhelming Stat That May Have You Thinking Twice About Buying Pfizer's Stock
(NYSE: PFE) can be a polarizing stock to own right now. Its future remains hazy given that it is facing some troubling patent cliffs and revenue from its COVID-19 vaccine is dwindling. But at the same time, the shares look cheap, and they could possess a lot of upside in the long run. Investors, however, aren't exactly loading up on the stock. Year to date, it's down around 3%.
The shares' trajectory can be difficult to predict given the uncertainty around the business. And there's a troubling stat that could have you thinking twice about Pfizer and whether it's really worth buying -- especially if you're a growth investor.
The past doesn't predict the future, but it can give investors a good insight into how a stock typically performs. Growth stocks, while they may have a bad year here and there, typically do well over a long period and the better ones usually outperform the broader market.
Source Fool.com
Pfizer Inc. Stock
The stock is one of the favorites of our community with 28 Buy predictions and 4 Sell predictions.
As a result the target price of 41 € shows a positive potential of 44.65% compared to the current price of 28.35 € for Pfizer Inc..
